STOK241220C25000
- 0.00
- 0.000.00%
Stoke Therapeutics Newsroom
CCORF Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $20
J.P. Morgan Maintains Stoke Therapeutics(STOK.US) With Hold Rating, Raises Target Price to $15
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $15 to $35
Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Immatics (IMTX)
Stoke Therapeutics' Zorevunersen Shows Promising Efficacy in Reducing Seizures and Improving Quality of Life, Justifying Buy Rating
Stoke Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Stoke Therapeutics Analyst Ratings
Leerink Partners Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Cuts Target Price to $18
TD Cowen Maintains Stoke Therapeutics(STOK.US) With Buy Rating
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $29
H.C. Wainwright Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $35
Stoke Therapeutics Analyst Ratings
Buy Rating Affirmed for Stoke Therapeutics Amid Solid Q2 Performance and Regulatory Progress
Stoke Therapeutics Price Target Maintained With a $22.00/Share by Needham
Buy Rating Reaffirmed for Stoke Therapeutics Amidst Clinical Progress and Strong Financial Footing
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics (STOK) Receives a Buy From Wedbush
Stoke Therapeutics Analyst Ratings
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)